Novo Nordisk's first GLP-1 obesity pill launched in the US
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, outside Copenhagen, on November…
Biotechnology
Pfizer's 2026 guidance shows deals with Metsera and Seagen will take time to bear fruit
Smith Collection | Stock Photos | fake images Pfizer It forecast modest guidance for 2026 on Tuesday as it looks…
Eli Lilly's Anti-Obesity Pill Maintains Weight Loss After Wegovy, Zepbound
The Eli Lilly & Co. logo at the company's Digital Health Innovation Hub facility in Singapore, Thursday, Nov. 14, 2024.…
How donors, access and polls led Trump to reclassify marijuana
President Donald Trump's decision Thursday to sign an executive order easing federal restrictions on marijuana (and clearing the way for…
UnitedHealth Group Releases Independent Audit Results
A UnitedHealthcare sign is displayed on its office building in Minnetonka, Minnesota, U.S., on Dec. 11, 2025. Tim Evans |…
Trump reclassifies cannabis to Schedule III, easing restrictions on marijuana
US President Donald Trump sits in the Oval Office to sign executive orders, at the White House in Washington, DC,…
Medline Debuts on Nasdaq After Largest IPO of 2025
Shares of the American medical supply giant Medline jumped in its debut on the Nasdaq on Wednesday after the largest…
Pfizer reaches agreement with YaoPharma for an anti-obesity pill
Pfizer CEO Albert Bourla speaks during a press conference with European Commission President Ursula von der Leyen after a visit…
Zealand Pharma unveils 2030 plan as weight loss competition heats up
Celsopupo | Stock | fake images Zealand Pharma outlined an ambitious five-year strategy for its anti-obesity portfolio on Thursday, highlighting…
Eli Lilly's weight-loss drug retatrutide clears first late-stage study
The Eli Lilly logo appears at the company's office in San Diego, California, USA, on November 21, 2025. Mike Blake…